Ming-Ming Li (Mingming Li)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Sentinel Lymph Node

Top Venues

Nature communications

Disease markers

This page only lists publications with an associated author ORCID identifier.

Publications

Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Xin Wang, Ming-Ming Li, Ye Niu, Xin Zhang, Ji-Bin Yin, Chang-Jiu Zhao, Rui-Tao Wang
Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma. Disease markers 2019 (2019)